Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Chugai to Market Modified Version of Tamiflu in Japan
July 31, 2006
- World's 1st Transdermal Agent for AD under Development by Novartis
July 31, 2006
- Anti-Parkinson's Drug KW-6002 Expected to Become Major Product: Kyowa Hakko
July 31, 2006
- SELF-MEDICATION NEWS IN BRIEF
July 31, 2006
- Covance Dedicates Itself to Development Service
July 31, 2006
- REGULATORY NEWS IN BRIEF
July 31, 2006
- MEDICAL DEVICE NEWS IN BRIEF
July 31, 2006
- JPMA Petition Calls For Increases in PMDA Reviewers
July 31, 2006
- SEMINAR
July 31, 2006
- Anact C's Approval Recommended for Purpura Fulminans
July 31, 2006
- Japanese Breast Cancer Society Drug Treatment Guidelines Amended
July 31, 2006
- COMMENTARY an article
July 31, 2006
- Arteriosclerosis Treatment GL under Amendment
July 31, 2006
- 1st Committee Recommends 3 New Drugs for Approval
July 31, 2006
- Leukemia Treatment Advances with Approval of Glivec
July 31, 2006
- Korosho to Again Cut \220 Billion in Natural Hike in Social Security Spending in FY2007
July 31, 2006
- 14th Clinical Pharmacy Symposium
July 31, 2006
- SEMIANR
July 31, 2006
- NEW PRODUCTS
July 31, 2006
- BUSINESS NEWS IN BRIEF
July 31, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…